- Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly, FDA-approved for type 2 diabetes and widely used off-label for weight loss. Zepbound is the weight-loss branded version of the same drug.
- Unlike semaglutide (Ozempic/Wegovy), tirzepatide targets two receptors — GIP and GLP-1 — which may explain its higher average weight loss in clinical trials.
- The SURMOUNT-1 trial showed an average weight loss of 22.5% of body weight at the 15mg dose over 72 weeks — the highest published result for any injectable weight-loss medication.
- Dose escalation takes at least 20 weeks to reach the maximum 15mg dose, with six dose levels from 2.5mg to 15mg. Many patients achieve strong results at lower doses.
- Tracking injections, side effects, weight trends, and meals with a companion app is essential during the multi-month escalation and helps your doctor make better dosing decisions.
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication manufactured by Eli Lilly. The FDA approved Mounjaro in May 2022 for improving blood sugar control in adults with type 2 diabetes. While Mounjaro does not yet carry an FDA weight-loss indication, its sister brand Zepbound (also tirzepatide) was FDA-approved in November 2023 specifically for chronic weight management. In practice, many patients receive Mounjaro off-label for weight loss, and the two products contain the same active ingredient at the same doses.
What sets tirzepatide apart from semaglutide-based medications like Ozempic and Wegovy is its mechanism: tirzepatide is a dual-action drug that targets both the GIP and GLP-1 receptors, rather than GLP-1 alone. This dual approach appears to produce greater weight loss and comparable or improved metabolic benefits compared to single-receptor GLP-1 agonists.
How Does Mounjaro Work?
Tirzepatide is the first FDA-approved medication to activate both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors simultaneously. Both are incretin hormones — natural gut signals released after you eat — but they work through complementary pathways:
- GLP-1 receptor activation. Like semaglutide, tirzepatide stimulates GLP-1 receptors in the brain's appetite centers, reducing hunger and increasing satiety. It also slows gastric emptying, so food stays in the stomach longer and you feel full after smaller meals. Patients commonly describe a significant reduction in "food noise" — the persistent mental preoccupation with eating.
- GIP receptor activation. This is what makes tirzepatide unique. GIP receptors are found in fat tissue, the pancreas, and the brain. Activating them appears to enhance fat metabolism, improve insulin sensitivity beyond what GLP-1 alone achieves, and may contribute to greater appetite suppression through a separate neural pathway. The exact mechanisms are still being studied, but the clinical data suggests the dual approach delivers meaningfully more weight loss.
- Improved insulin and glucose regulation. Tirzepatide enhances the body's insulin response to food while reducing glucagon (a hormone that raises blood sugar). This helps stabilize blood sugar throughout the day, which can reduce cravings and energy crashes — particularly valuable for patients with insulin resistance or prediabetes.
Like semaglutide, tirzepatide is injected once weekly. It has a half-life of approximately 5 days, and drug levels reach steady state after about 4 weeks at each dose — which is why the dose escalation schedule builds gradually over months.
Mounjaro Dose Escalation Schedule
Mounjaro uses a six-step dose escalation that takes a minimum of 20 weeks to reach the maximum dose. Each step lasts at least 4 weeks, giving your body time to adjust before moving to the next level:
| Period | Dose | What to Expect |
|---|---|---|
| Weeks 1-4 | 2.5mg | Starting dose. Not yet a therapeutic dose for weight loss. Mild appetite changes; some patients notice light nausea or reduced hunger. |
| Weeks 5-8 | 5mg | First therapeutic dose. Appetite reduction becomes more noticeable. Early weight loss often begins here. Nausea may return briefly at the step-up. |
| Weeks 9-12 | 7.5mg | Appetite suppression strengthens. Consistent weight loss for most patients. GI side effects typically improving by this stage. |
| Weeks 13-16 | 10mg | Strong appetite reduction. Many patients see their most significant weight-loss acceleration. Some experience renewed GI symptoms at this step. |
| Weeks 17-20 | 12.5mg | Near-maximum dose. Pronounced effects on hunger and fullness. Patients who tolerate this dose well often continue to 15mg. |
| Week 21+ | 15mg | Maximum dose. Highest level of appetite suppression and weight-loss effect. Steady state reached in approximately 4 weeks. |
What Do the Clinical Trials Show?
Mounjaro's weight-loss data comes primarily from the SURMOUNT clinical trial program. The headline results from SURMOUNT-1 (published in the New England Journal of Medicine) studied tirzepatide in adults with obesity or overweight without type 2 diabetes:
- Average weight loss at 15mg: 22.5% of body weight over 72 weeks — roughly 52 lbs for someone starting at 230 lbs.
- Average weight loss at 10mg: 21.4% of body weight over the same period.
- Average weight loss at 5mg: 15.0% of body weight — still a substantial result, comparable to semaglutide 2.4mg.
- Clinically meaningful thresholds: 96% of participants on the 15mg dose lost at least 5% of their body weight. 63% lost at least 20%. More than a third (36%) lost at least 25%.
- Metabolic improvements: Significant reductions in waist circumference, blood pressure, triglycerides, fasting insulin, and A1C levels across all dose groups.
These numbers represent the highest average weight loss published for any injectable GLP-1 class medication. In head-to-head comparisons with semaglutide, tirzepatide has consistently shown a greater degree of weight loss, likely attributable to the additional GIP receptor activity. The SURMOUNT-2 trial, which studied patients with both obesity and type 2 diabetes, showed average weight loss of 14.7% at 15mg — still clinically significant, though modestly lower than the non-diabetic cohort.
Common Side Effects
Mounjaro's side effect profile is similar to semaglutide-based medications because both drug classes affect gut motility and appetite signaling. The most common side effects are gastrointestinal:
- Nausea (up to 31% in trials) — Most common in the first 1-2 weeks after each dose escalation. Tends to diminish as your body adjusts. Eating smaller, more frequent meals and avoiding greasy foods helps significantly.
- Diarrhea (up to 23%) — Usually mild and temporary, most often during the transition between doses.
- Constipation (up to 11%) — Less common than with semaglutide in some studies. Staying well-hydrated and eating fiber-rich foods helps.
- Decreased appetite (up to 20%) — This is both a side effect and the intended mechanism. It's listed because some patients find the appetite reduction more dramatic than expected, particularly at higher doses.
- Injection site reactions (up to 7%) — Redness, itching, or mild swelling at the injection site. Rotating between abdomen, thigh, and upper arm reduces occurrence.
Most GI side effects improve within 2-4 weeks at each dose level. The six-step escalation schedule exists specifically to minimize these effects by allowing gradual adaptation. For a detailed week-by-week breakdown of what to expect, see our guide on GLP-1 side effects in the first month.
Mounjaro vs Ozempic & Wegovy: Key Differences
All three medications belong to the incretin-based therapy class, but there are meaningful distinctions:
- Receptor targets: Mounjaro/Zepbound (tirzepatide) targets both GIP and GLP-1 receptors. Ozempic/Wegovy (semaglutide) targets GLP-1 only. This dual mechanism is the primary reason tirzepatide shows higher average weight loss in clinical trials.
- Weight-loss magnitude: SURMOUNT-1 showed 22.5% average weight loss at the highest tirzepatide dose over 72 weeks. STEP 1 showed 14.9% for semaglutide over 68 weeks. While these trials have different designs and aren't a perfect comparison, the trend is consistent across available data.
- Manufacturer: Mounjaro/Zepbound is made by Eli Lilly. Ozempic/Wegovy is made by Novo Nordisk. Different manufacturers mean different supply chains, pen designs, and coupon programs.
- FDA approvals: Mounjaro is approved for type 2 diabetes. Zepbound is approved for weight management. Ozempic is approved for type 2 diabetes. Wegovy is approved for weight management. The choice between brands often depends on your insurance formulary and primary treatment goal.
- Dose range: Mounjaro offers six dose levels (2.5mg to 15mg) with more granular escalation steps. Wegovy has five levels (0.25mg to 2.4mg). More steps may offer more flexibility in finding the right maintenance dose.
From a behavioral and tracking standpoint, these medications work similarly: they reduce appetite, slow digestion, and give patients more control over eating decisions. The behavioral strategies that complement treatment — meal awareness, injection tracking, side effect logging, daily reflection — are the same regardless of which medication you're on.
How to Track Your Mounjaro Treatment
With six dose levels and a 20+ week escalation, Mounjaro arguably demands more careful tracking than any other GLP-1 medication. Each dose step brings new adjustments, and without a clear record, it's nearly impossible to recall how you responded at 7.5mg versus 10mg when your doctor asks at your next appointment.
What to track:
- Injection log. Date, time, dose, and injection site for every shot. With six dose levels, a clean injection history becomes your most valuable reference for dosing conversations with your provider.
- Side effects by dose level. Note which symptoms appear, their severity, and how long they last at each new dose. This information directly informs whether to continue escalating, hold at the current dose, or step back.
- Weight trend. Weekly or daily weigh-ins — just stay consistent. Focus on the 4-8 week moving trend rather than daily fluctuations. Weight-loss rate often varies between dose levels, and seeing that pattern over time is reassuring.
- Meal check-ins. A simple supportive/unsupportive assessment builds awareness of how your eating patterns shift as tirzepatide takes effect. Many patients notice dramatic changes in portion sizes and food preferences between 5mg and 10mg. You don't need to count anything — learn about the meal awareness approach instead.
A GLP-1 companion app like MyWhy handles all of this in one place — injection tracking with drug-level visualization, meal check-ins, weight trends, and daily reflections. Everything is free. See how it compares in our best free GLP-1 tracking apps guide.